Nationwide recall of mango-scented antiseptic foam wash from Abc Compounding enters FDA records
A Class II recall of a hand and body wash made by Abc Compounding, over manufacturing-practice deviations, remains open and spans the entire US market.
A foam antiseptic wash sold as Handtastic Foamy Mango is the subject of an open nationwide recall, after the US Food and Drug Administration logged the action in its enforcement report of 4 November 2026. The manufacturer is Abc Compounding Co., Inc.
The agency has filed the action as recall D-0095-2027 and classed it as Class II. The stated trigger is deviations from current good manufacturing practice (CGMP). The FDA shows the recall as ongoing, so it has not been formally closed. Distribution is recorded as covering the whole of the United States.
The commercial impact cannot be gauged from the entry as we have it. The material does not describe what the CGMP deviations were, which lots are affected, how much product is involved or when the firm began the recall. Nor does it say anything about sales, returns, replacement costs or customers. We have therefore not attempted to size the financial consequences for the company.
By way of general context, the FDA applies the Class II label where using or being exposed to a product may lead to temporary or medically reversible adverse health effects, or where the likelihood of serious harm is remote. Details such as product codes, lot information and the firm's stated reason sit in the full enforcement report entry.
Why it matters
- A recall can be driven by manufacturing-practice deviations alone, which matters for makers of topical antiseptics and for the contract manufacturers that supply them.
- Because the recall is open and national in scope, distributors and retailers that handled the product have reason to watch for recall notices.
- The cost to Abc Compounding is not disclosed, and the lot and volume details needed to size the exposure are not in the available material.
Official record: FDA enforcement report ↗
Written by CompePharma's editorial system from the official record. AI-assisted; check the source before acting. Not investment advice.